



Contact:

Robert Gottlieb
RMG Associates, LLC
857-891-9091
Robertmg52@gmail.com

Cellanyx places third in annual MALSI day poster competition.

Beverly, MA, July 1st, 2017 – Cellanyx’s live cell phenotypic biomarker test data demonstrating the potential to stratify prostate cancer risk from ‘normal’ [field] tissue obtained away from the known area of tumor, was awarded third place in the poster competition at the [2017 Massachusetts Life Sciences Innovation Day Research & Start-Up Showcase](#). This award, along with Cellanyx’s recent award for the best prostate cancer biomarker poster at the AdMeTech Foundation Global Summit underscores the growing recognition of the potential for the company’s live cell phenotypic biomarker platform. Cellanyx is developing a prostate cancer phenotypic biomarker test to assess tumor aggressiveness and metastatic potential. Cellanyx’s test will complement the standard-of-care Gleason pathology scores to allow improved risk-stratification in prostate cancer.

Biopsies to detect prostate cancer sample less than one percent of the prostate gland, and as a result, about half of random prostate biopsies are negative and this leads to the need for re-biopsy in a significant percentage of men.

Cellanyx presented data from 60 prostate tissue samples taken at the time of radical prostatectomy (RP) from tissue away from the known area of cancer (referred to as ‘field tissue’ samples). The “field” samples were part of a larger blinded, multi-center clinical validation study in 250 RP specimens at the time of surgery.

The Cellanyx test predicted adverse pathology from both, the “field” and known tumor samples with greater than 85 percent sensitivity and specificity by Receiver Operator Curves (ROC) by Area Under the Curve (AUC) measurements. Cellanyx plans to conduct a prospective, clinical utility study in patients undergoing needle biopsies to compare its predictive phenotypic biomarker metrics to adverse pathologic features found in men who subsequently undergo RP.

About Cellanyx

Cellanyx is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company's unique 'biopsy-on-a-chip' methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with prostate cancer. Learn more at www.cellanyx.com.

Contact:

Ashok Chander, CEO
ashok@cellanyx.com
978 473 7883

Robert Gottlieb, RMG Associates, LLC
Robertmg52@gmail.com
857 891 9091

###